Bone phenotype in patients with kidney failure with and without type 2 diabetes
Authors' conclusion
In conclusion, patients with kidney failure and T2DM have preserved BMD compared with patients without diabetes.
Study context
- Population
- Patients with kidney failure at the time of kidney transplantation; type 1 DM excluded; T2D median HbA1c 6.2%BMD n = 555
- Participants
- 647 patients
- Exposure
- T2D vs non-T2D in kidney failure
- T2DMn = 102
- Outcome
- Bone phenotype: BTM, sclerostin and BMD
Main finding
As reported in the abstract
- Lower in T2DM; unadjusted
- intact P1NP 68 vs 82 μg/L; P = 0.03
- Higher in T2DM; unadjusted
- sclerostin 2.1 vs 1.8 ng/mL; P = 0.04
- Higher in T2DM
- lumbar spine BMD Z-score −0.066 vs −0.760; P < 0.001
- Higher in T2DM
- femoral neck BMD Z-score −0.680 vs −0.965; P = 0.04
Observational data: associations, not effects.
Further findings
| Outcome | non-T2DM |
|---|---|
| Correlation of HbA1c with BTM and BMD (only in non-T2DM) | |
| BALP ρ | −0.12 (p = .007) |
| Intact P1NP ρ | 0.14 (p = .002) |
| TRACP5b ρ | −0.13 (p = .003) |
| Lumbar spine BMD ρ | 0.12 (p = .008) |
| Femoral neck BMD ρ | 0.11 (p = .02) |
| Total hip BMD ρ | 0.17 (p < .001) |
Correlation of HbA1c with bone turnover markers (BTM) and BMD (only in non-T2DM)
- No correlation in T2DM
Original publication
Bone phenotype in patients with kidney failure with and without type 2 diabetes. J Bone Miner Res. Published 28 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →